ArticleThe Journal of dermatology2019

Efficacy and safety of topical OPA-15406, a new phosphodiesterase 4 inhibitor, in Japanese patients with atopic dermatitis for 8 weeks: A phase 2, randomized, double-blind, placebo-controlled study.

Hidehisa Saeki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.